4.5 Article

Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure

Journal

JACC-HEART FAILURE
Volume 9, Issue 12, Pages 890-903

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.jchf.2021.07.001

Keywords

acute heart failure; blood pressure; renal dysfunction

Funding

  1. Novartis
  2. American Heart Association
  3. National Institutes of Health
  4. Rocket Pharma
  5. Abbott Laboratories
  6. Amgen
  7. Celyad
  8. Cirius Therapeutics
  9. Roche Diagnostics
  10. Sanofi
  11. Windtree Therapeutics
  12. National Heart, Lung, and Blood Institute
  13. Bayer Merck
  14. Cytokinetics
  15. Servier
  16. Medtronic
  17. Vifor
  18. Boehringer Ingelheim
  19. Bayer
  20. Bristol Myers Squibb
  21. Roche
  22. Patient-Centered Outcomes Research Institute
  23. Agency for Healthcare Research and Quality, OrthoDiagnostics
  24. Vifor Pharma
  25. MyoKardia
  26. Novo Nordisk
  27. AbbVie
  28. AstraZeneca
  29. EBR Systems

Ask authors/readers for more resources

In patients hospitalized for acute heart failure, a significant early drop in systolic blood pressure was associated with increased risk for worsening renal function, worsening heart failure, and 180-day cardiovascular death. However, the association between systolic blood pressure drop and prognosis was not influenced by worsening renal function.
OBJECTIVES The aim of this study was to investigate the association between systolic blood pressure (SBP) drop, worsening renal function (WRF), and prognosis in patients with acute heart failure (AHF). BACKGROUND A large drop in SBP early after hospital admission for AHF might be associated with increased risk for WRF and prognosis. However, there is a paucity of data regarding the interaction between WRF and a drop in SBP on clinical outcomes. METHODS A post hoc analysis among 6,544 patients with AHF enrolled in the RELAX-AHF-2 (Relaxin in Acute Heart Failure-2) trial was performed. Blood pressure was uniformly and repetitively measured. Peak SBP drop was defined as the difference between baseline SBP and lowest SBP documented during the first 48 hours. WRF was defined by an increase in serum creatinine of $0.3 mg/dL from baseline to day 5. RESULTS Peak SBP drop was independently associated with a higher risk for WRF (HR: 1.11 per 10 mm Hg SBP drop; P < 0.001), 5-day worsening heart failure (HR: 1.12 per 10 mm Hg SBP drop; P = 0.006), and 180-day cardiovascular death (HR: 1.09 per 10 mm Hg SBP drop; P = 0.026) after adjustment for potential confounders including baseline SBP. There was no interaction between the prognostic value of early SBP drop according to the presence or absence of WRF. CONCLUSIONS In patients hospitalized for AHF, a greater early drop in SBP was associated with a higher incidence of WRF, worsening heart failure, and an increased risk for 180-day cardiovascular death. However, the association between SBP drop and prognosis was not influenced by WRF. (Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF [RELAX-AHF-2]; NCT01870778) (J Am Coll Cardiol HF 2021;9:890-903) (c) 2021 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available